Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report

BACKGROUND: Pulmonary sarcomatoid carcinoma is a rare non-small-cell lung cancer (NSCLC) subtype with a poor prognosis. In the phase III PACIFIC study, durvalumab significantly improved progression-free survival and overall survival versus placebo, in patients with stage III NSCLC who do not have di...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishino, Kazumi, Kunimasa, Kei, Kimura, Madoka, Inoue, Takako, Tamiya, Motohiro, Kuhara, Hanako, Kumagai, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118808/
https://www.ncbi.nlm.nih.gov/pubmed/32245391
http://dx.doi.org/10.1186/s40360-020-00404-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118808/
https://www.ncbi.nlm.nih.gov/pubmed/32245391
http://dx.doi.org/10.1186/s40360-020-00404-7

Ejemplares similares